BR112019020421A8 - Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres - Google Patents
Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceresInfo
- Publication number
- BR112019020421A8 BR112019020421A8 BR112019020421A BR112019020421A BR112019020421A8 BR 112019020421 A8 BR112019020421 A8 BR 112019020421A8 BR 112019020421 A BR112019020421 A BR 112019020421A BR 112019020421 A BR112019020421 A BR 112019020421A BR 112019020421 A8 BR112019020421 A8 BR 112019020421A8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- inhibitors
- cancer
- treatment
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A presente invenção refere-se a compostos de Fórmula I ou sais ou solvatos farmaceuticamente aceitáveis dos mesmos. A invenção refere-se adicionalmente ao uso dos compostos de Fórmula I como inibidores de A2A. A invenção também se refere ao uso dos compostos da Fórmula (I) para o tratamento e/ou a prevenção de câncer. A invenção também se refere a um processo para a fabricação de compostos da Fórmula I.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163781 | 2017-03-30 | ||
| US201762565281P | 2017-09-29 | 2017-09-29 | |
| EP17194084 | 2017-09-29 | ||
| ARP180100778A AR111200A1 (es) | 2017-03-30 | 2018-03-28 | Derivados de tiocarbamato como inhibidores de a2a y métodos para usar en el tratamiento de cánceres |
| PCT/EP2018/058301 WO2018178338A1 (en) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112019020421A2 BR112019020421A2 (pt) | 2020-04-28 |
| BR112019020421A8 true BR112019020421A8 (pt) | 2022-11-08 |
Family
ID=61911575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019020421A BR112019020421A8 (pt) | 2017-03-30 | 2018-03-30 | Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10995101B2 (pt) |
| EP (2) | EP4112623A1 (pt) |
| JP (2) | JP7197558B2 (pt) |
| KR (2) | KR102640927B1 (pt) |
| CN (3) | CN110678472B (pt) |
| AU (1) | AU2018246355B2 (pt) |
| BR (1) | BR112019020421A8 (pt) |
| CA (1) | CA3058260A1 (pt) |
| DK (1) | DK3601296T3 (pt) |
| ES (1) | ES2926158T3 (pt) |
| HR (1) | HRP20221039T1 (pt) |
| HU (1) | HUE059990T2 (pt) |
| IL (2) | IL300149A (pt) |
| LT (1) | LT3601296T (pt) |
| MX (2) | MX2019011743A (pt) |
| PL (1) | PL3601296T3 (pt) |
| RS (1) | RS63557B1 (pt) |
| RU (1) | RU2019134724A (pt) |
| SI (1) | SI3601296T1 (pt) |
| TW (1) | TWI836960B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111093666A (zh) | 2017-07-18 | 2020-05-01 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| AU2018302179A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| AU2019337974A1 (en) * | 2018-09-11 | 2021-04-08 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| JP2022517419A (ja) | 2019-01-18 | 2022-03-08 | ニューベイション・バイオ・インコーポレイテッド | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| TWI288137B (en) * | 2000-05-26 | 2007-10-11 | Schering Corp | Adenosine A2a receptor antagonists |
| WO2004092171A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
| ES2342082T3 (es) * | 2004-04-21 | 2010-07-01 | Schering Corporation | Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina. |
| WO2007140181A2 (en) | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
| US7691869B2 (en) * | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| TW200914048A (en) | 2007-07-17 | 2009-04-01 | Combinatorx Inc | Combinations for the treatment of B-cell proliferative disorders |
| US20110237599A1 (en) | 2010-03-10 | 2011-09-29 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| US9006177B2 (en) | 2010-09-24 | 2015-04-14 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| EP3570844B1 (en) | 2017-01-20 | 2023-09-06 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
| TWI801372B (zh) * | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
| JP7391022B2 (ja) | 2017-12-19 | 2023-12-04 | インペティス・バイオサイエンシーズ・リミテッド | がんの処置のための医薬組成物 |
| AU2019337974A1 (en) | 2018-09-11 | 2021-04-08 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| WO2020065036A1 (en) | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
-
2018
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/hr unknown
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/zh active Active
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en active Pending
- 2018-03-30 MX MX2019011743A patent/MX2019011743A/es unknown
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/pl unknown
- 2018-03-30 RS RS20220794A patent/RS63557B1/sr unknown
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/zh active Pending
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/da active
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/ja active Active
- 2018-03-30 SI SI201830747T patent/SI3601296T1/sl unknown
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/hu unknown
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/ko active IP Right Grant
- 2018-03-30 ES ES18716193T patent/ES2926158T3/es active Active
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/ko active Application Filing
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/pt unknown
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/zh active Pending
- 2018-03-30 RU RU2019134724A patent/RU2019134724A/ru not_active Application Discontinuation
- 2018-03-30 TW TW112113401A patent/TWI836960B/zh active
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/lt unknown
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
-
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/es unknown
-
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
-
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en active Pending
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019020421A8 (pt) | Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres | |
| BR112018070859A2 (pt) | degradantes da proteína de bet | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| BR112016006651A8 (pt) | derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos. | |
| CY1121444T1 (el) | Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων | |
| BR112017020900A2 (pt) | compostos de 1-ciano-pirrolidina como inibidores de usp30 | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| BR112014027236A2 (pt) | pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas | |
| BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
| BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
| BR112015017878A2 (pt) | composto da fórmula estrutural ii, composto da fórmula estrutural iii, composição farmacêutica e método de tratamento de um distúrbio mediado por vmat2 | |
| BR112018013977A2 (pt) | derivados de quinolin-2-ona | |
| CR20180091A (es) | 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
| BR112019004248A2 (pt) | inibidores da dopamina-b-hidroxilase | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: ITEOS BELGIUM SA (BE) |